{"id":"tak-667","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5970190","moleculeType":null,"molecularWeight":"463.54"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the CD47-SIRPα interaction, TAK-667 enhances the ability of macrophages to recognize and engulf tumor cells, leading to their destruction. This mechanism is thought to be particularly effective in the context of hematologic malignancies, where tumor cells often express high levels of CD47.","oneSentence":"TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT04654351","phase":"PHASE3","title":"A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-01-15","conditions":"Hereditary Angioedema","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Icatibant"],"phase":"phase_3","status":"active","brandName":"TAK-667","genericName":"TAK-667","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}